mometasone furoate + oxymetazoline

Mometasone furoate + oxymetazoline is a fixed-dose combination of two intranasal agents used for the treatment of seasonal allergic rhinitis and nasal congestion. Mometasone furoate is a medium-potency synthetic corticosteroid that acts as an agonist at the glucocorticoid receptor to suppress inflammation by inducing inhibitory proteins (lipocortins) that control the biosynthesis of inflammatory mediators such as prostaglandins and leukotrienes[1][6]. Oxymetazoline is an imidazole derivative and direct-acting alpha-adrenergic agonist with high affinity for alpha-1A adrenoceptors; it produces rapid vasoconstriction in nasal mucosa to relieve congestion[4]. The combination leverages both anti-inflammatory effects from mometasone and fast decongestant action from oxymetazoline. Clinical studies show this dual-mechanism approach provides superior symptom relief—especially for nasal congestion—compared to either agent alone in patients with seasonal allergic rhinitis[5][2].